Skip to main content
BI

BIOMEDICAN, Inc.

This biotech startup utilizes yeast fermentation to produce organic, non-GMO rare cannabinoids, enabling the efficient synthesis of pharmaceutical-grade compounds at a lower cost than traditional methods. By providing these high-quality cannabinoids, the company supports research and development in synthetic biology and cellular agriculture.

Fremont, United StatesFounded 2017132K+ followers
Updated 18 months ago

Funding

$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

H
Funding rounds are not available yet.

Founders

Product

Problem

The traditional methods of extracting rare cannabinoids from plants are inefficient, costly, environmentally taxing, and subject to inconsistent yields and regulatory oversight. Chemical synthesis, while an alternative, often results in artificial compounds with undesirable side effects.

Solution

Biomedican utilizes a patented biosynthesis process involving the fermentation of a proprietary strain of Yarrowia Lipolytica (YL) yeast to produce pharmaceutical-grade, 100% organic, non-GMO rare cannabinoids. This method allows for the efficient and scalable production of cannabinoids that are bioidentical to those found in nature, without the need for plant cultivation or chemical synthesis. The fermentation process requires only sugar, water, and the YL yeast, resulting in a production cost that is 70-90% lower than conventional methods.

Target Audience

The primary customers are pharmaceutical companies, the cosmetics industry, the food industry, nutraceutical companies, and clinical researchers seeking high-quality, rare cannabinoids for research and product development.

Features

  • Patented biosynthesis method using proprietary Yarrowia Lipolytica (YL) yeast
  • Production of 100% organic, non-GMO cannabinoids
  • Production of CBG, CBGA, CBN, CBNA, THCA, and THCV
  • Pharmaceutical-grade quality compounds, identical to those found in nature
  • High-volume production through a fast, scalable, and environmentally friendly fermentation process
  • Production costs 70-90% lower than conventional methods
  • Option to produce psilocybin, DMT, 5-MeO-DMT, and mescaline
This profile is AI-generated and may contain inaccuracies.